Inventiva S.A.
IVA
Pozycja w akcjach
#10373
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Cena akcji
$3.39
Kapitalizacja rynkowa
$801.14M
Zmiana (1 dzień)
-3.05%
Zmiana (1 rok)
-8.16%
Kraj
FR
Handel Inventiva S.A. (IVA)
Kategoria
Healthcare
Historia ceny akcji dla Inventiva S.A. (IVA)
Najwyższa cena zamknięcia: $3.42 dnia 2026-10-01
Najniższa cena zamknięcia: $11.50 dnia 2021-08-01
Najniższa cena zamknięcia: $11.50 dnia 2021-08-01
Historia cen akcji firmy Inventiva S.A. od 2021 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 11.32% |
| 2025 | 81.18% |
| 2024 | -45.73% |
| 2023 | -3.30% |
| 2022 | -66.26% |
| 2021 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $530.27 | 24.35% |
US
|
|
| $238.46 | 788.12% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $892.62 | 9.64% |
NL
|
|
| $287.83 | 1.13% |
BE
|
